Please Wait...

Regulatory Expertise

Led by tenured senior executives with extensive clinical research experience, Bioclinica's global cardiac safety and efficacy regulatory expertise is second to none. Bioclinica's unmatched regulatory leadership is well recognized and backed by ongoing professional relationships with key authorities and panels. We have worked with the ICH and FDA to advance industry standards and guidance in the conduct of TQT studies and have successfully completed the first ever regulatory mandated TQT studies in both Japan and China. Bioclinica has supported the design and specific cardiac monitoring technology for our sponsors on studies requested by regulatory authorities. The data from such studies has met the predefined goals established by both sponsor and regulatory organizations.

Bioclinica's regulatory services include:

  • Protocol consultation and guidance throughout development life cycle
  • Fast-tracked ECG and imaging data regulatory submissions and archiving
  • Audit preparation and support
  • FDA ECG warehouse submission
  • Integrated Cardiac Safety Summary reports in support of the alternative approach to formal TQT study requirements

Industry Associations

Bioclinica continues to accelerate drug development, working in tandem with regulatory bodies and key clinical research associations to establish and maintain core lab industry standards for cardiac safety services.

Our contributions include interaction with the following:

  • Metrics Champion Consortium (MCC)
  • Cardiac Safety Research Consortium (CSRC)
  • International CardioOncology Society (ICOS)
  • ICH-E14 expert advisory panel
  • American Society of Hypertension (ASH)
  • American Telemedicine Association (ATA)
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @endpts: #FDA revises draft guidance on #raredisease drug R&D https://t.co/KaNVw54MDE by @ZacharyBrennan via @RAPSorg
Bioclinica (8 hours ago)
RT @PrimeVigilance: News and Press Release - Source @EMA_News now available monthly meeting highlights from #Pharmacovigilance #RiskAssessm…
Bioclinica (8 hours ago)
RT @FDA_Drug_Info: New #FDA Draft Guidance for Industry on Rare Diseases – Common Issues in Drug Development: https://t.co/yxaGyMB7hY. http…
Bioclinica (8 hours ago)
Looking to exercise DDDM in clinical trials? Get tips on obtaining, distilling and presenting data in our new white… https://t.co/NkGrS9JnG8
Bioclinica (10 hours ago)
Is your clinical study supply chain management solution increasing the risk of stock out? Ehsan Ramezani gives pers… https://t.co/YCfP3wCvK6
Bioclinica (Yesterday)
Bioclinica's Kate Adamczuk is presenting at #HAI2019 today! Details on this and other scientific findings at HAI… https://t.co/wDQr6ldfcS
Bioclinica (Yesterday)

Latest Blogs:

Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner